- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Roger Brito on When Providers Should Be Involved in Reimbursement Model Development
Providers should be involved in new reimbursement model development from day 1, said Roger Brito, DO, national director for oncology, Aetna.
Providers should be involved in new reimbursement model development from day 1, said Roger Brito, DO, national director for oncology, Aetna.
Transcript (slightly modified)
When a new reimbursement model is being developed, at what stage should providers become involved?
My goal is that we should be involved from day 1. I was in practice for almost 20 years before joining Aetna, and the last time that I spoke to a provider as on oncologist was when they were denying some type of care plan that I was requesting. So, this is a 360-degree change. We communicate and collaborate together. I feel that from a provider perspective and with our oncology medical home models, which parallel the oncology care model, we should work together on coming up with what the ideal payment plan is going to be, and that’s our goal.
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
